WT1致敏树突状细胞激活CTLs对HL60细胞作用的研究

目的研究分别负载WT1多肽抗原及HL60细胞冻融抗原的树突状细胞(DCs)产生的特异性细胞毒性T淋巴细胞(CTLs)对HL60细胞的杀伤效应。方法联合应用rhGM-CSF、rhIL-4、rhTNF-α及rh-sCD40L等细胞因子,诱导扩增自健康人外周血获取的单核细胞,培养出DCs,分别用WT1多肽抗原及冻融抗原冲击致敏,激活淋巴细胞。实验分4组WT1多肽致敏DCs为实验组A,HL60细胞冻融抗原致敏DCs为实验组B,未致敏DCs组为对照组A,单核细胞组为对照组B,LDH释放法检测CTLs对HL60细胞的杀伤作用。结果培养出具有典型特征的DCs,表达CD40达96%,CD80达77%,CD1α达69%,CD86达97%,体外能诱导强烈的同种异体混合淋巴结胞增殖反应。在效靶比为20∶1时,WT1多肽致敏DCs组时HL60细胞杀伤率为89.1%,冻融抗原负载DCs组为90.6%,未致敏DCs组为32.8%,单核细胞组为26.1%。以下多肽或冻融抗原负载DCs与对照组相比显示更强的杀伤效应,P<0.01。结论WT1多肽抗原及HL60细胞冻融抗原冲击致敏DCs均能有效诱导T细胞抗白血病作用,为临床研制DCs疫苗提供实验依据。     

肝癌细胞对重组人HSP70联合肝癌组织冻融抗原修饰树突状细胞的免疫应答

目的:研究重组人热休克蛋白70(rhHSP70)联合肝癌组织冻融抗原修饰的树突状细胞(dendritic cell,DC)诱导对肝癌细胞的免疫杀伤效应.方法:外周血单个核细胞经粒-巨噬细胞集落刺激因子(GM-CSF)、白细胞介素4 (IL-4)诱导生成DC,负载冻融抗原的同时加入rhHSP70,不同分组致敏的DC激活淋巴细胞生成肿瘤抗原特异性细胞毒性T淋巴细胞(cytotoxic T cells,CTL),四甲基偶氮唑蓝(MTT)法及3H-TdR法检测DC刺激淋巴细胞增殖能力, MTT法检测CTL对肝癌细胞的体外杀伤活性,酶联免疫吸附试验(ELISA)测定细胞因子的分泌,流式细胞术(FCM)检测DC表型变化.结果:冻融抗原致敏的DC可明显促进淋巴细胞增殖,能有效呈递肝癌冻融抗原,诱导产生抗原特异性CTL,联合rhHSP70能进一步增强CTL对肝癌细胞的杀伤作用.结论:肝癌冻融抗原联合rhHSP70修饰的DC诱导CTL对肝癌细胞能产生高效杀伤作用.     

抗原致敏及白细胞介素27基因修饰的树突状细胞诱导抗食管癌免疫的体外研究

目的:探讨食管癌细胞抗原致敏、白细胞介素27(interleukin27,IL-27)基因修饰的树突状细胞(dendritic cells,DCs)疫苗的特异性抗食管癌免疫反应。方法:采用重组逆转录病毒介导IL-27基因修饰食管癌患者外周血DCs;反复冻融法提取食管癌细胞裂解产物,致敏经IL-27基因转染的DCs;ELISA法检测各组DCs和细胞毒性T淋巴细胞(cytotoxic T lymphocytes,CTLs)上清液中IL-27、IL-12和干扰素-γ(interferon-γ,IFN-γ)的分泌水平;FCM法分析各组DCs表面分子CD1a、CD83、CD80和CD86的表达水平;MTT法检测DCs刺激T细胞增殖的活性和DCs诱导CTLs杀伤食管癌细胞的效能。结果:经IL-27基因修饰和抗原致敏后的DCs高表达CD83、CD80和CD86分子,其表达量分别为(82.67±7.92)%、(78.33±7.31)%和(85.33±4.32)%;DCs上清液中IL-12、IL-27及IFN-γ分泌量明显提高,分别为(107.85±7.20)ng/L、(430.39±10.12)ng/L及(411.97±17.80)ng/L;并且,DCs明显刺激同源T细胞增殖,增强了CTLs上清液中IFN-γ水平[(751.50±31.30)ng/L]。诱导产生的CTLs对食管癌细胞有强大的杀伤作用,显著高于其他组(P<0.01)。结论:IL-27基因修饰增强了DCs在体外诱导自体T淋巴细胞产生特异性抗食管癌免疫的能力。其机制可能与IL-27基因修饰和抗原致敏活化了DCs抗原提呈第二信号,促进了DCs高分泌IL-27和IL-12因子,活化了T淋巴细胞,并致使CTLs分泌IFN-γ的能力增强等密切相关。     

树突状细胞疫苗的制备及其体外诱导细胞毒性T淋巴细胞对宫颈癌CaSki细胞的杀伤作用

目的:制备树突状细胞(dendritic cells,DCs)疫苗并观察其在体外诱导细胞毒性T淋巴细胞(cytotoxic T lymphocytes,CTLs)对宫颈癌CaSki细胞的杀伤效应。方法:分离培养小鼠未成熟DCs,FCM检测小鼠未成熟DCs表面标志物CD40、CD86、主要组织相容性复合体-Ⅱ(major histocompatibility complex-Ⅱ,MHC-Ⅱ)和CD11c;将已成功构建的携带人乳头状瘤病毒(human papillomavirus,HPV)16E6E7基因的重组腺病毒pAd-E6E7感染体外培养的小鼠未成熟DCs,提取CaSki细胞裂解物负载DCs,制备DC疫苗,激光共聚焦显微镜下观察pAd-E6E7感染的小鼠未成熟DCs绿色荧光蛋白表达,Western印迹法检测E6蛋白的表达;DCs疫苗诱导产生CTLs后与CaSki细胞共培养,CCK8(cell countingkit8)法检测其对CaSki细胞的杀伤效应。结果:成功分离培养了小鼠未成熟DCs,并制备获得了HPV16E6E7特异性DCs疫苗。DCs疫苗诱导产生的CTLs对CaSki细胞具有杀伤作用,pAd-E6E7感染组对CaSki的杀伤效应明显高于CaSki细胞裂解物负载组及未处理DCs组(P<0.05)。结论:以携带HPV16E6E7基因的重组腺病毒感染DCs制备基因修饰的DCs疫苗,具有诱导CTLs体外杀伤子宫颈癌CaSki细胞的作用。     

DC活化淋巴细胞对自体乳腺癌细胞的杀伤作用

 目的探讨负载自体抗原DC诱导的CTLs对自体乳腺癌细胞的杀伤作用。方法以负载自体癌细胞抗原的DCs体外诱导CTLs,用ELISA法检测IFN-γ和IL-12的表达水平,用LDH法检测CTL对自体癌细胞的杀伤作用。结果负载自体抗原DC组IFN-γ和IL-12的浓度高于未致敏DC组、抗原组及单核细胞对照组(P<0.05),且负载抗原DC组所刺激的CTLs的杀伤作用也强于未致敏DC组、抗原组及单核细胞组(P<0.01)及对照的MCF-7组和HT-29组(P<0.01)。结论肿瘤裂解物致敏DC可持续刺激特异性CTLs从而可在体外杀伤乳腺癌患者的自体肿瘤细胞,说明肿瘤抗原致敏的DC疫苗对于治疗残留的和(或)对化疗耐药乳腺癌可能是适合的,因而有可能成为标准的补救措施。     

负载酸洗抗原肽的树突状细胞诱导抗膀胱癌的作用

目的研究弱酸洗脱法提取抗原肽致敏的树突状细胞(DCs)诱导针对膀胱癌细胞的特异性杀伤效应。方法弱酸洗脱法获得BI U-87细胞抗原肽,用GM-CSF、IL-4和TNF-α体外诱导正常人DC并负载肿瘤抗原,进而激活T淋巴细胞;用MTT法检测其对BI U-87体外杀伤效应。结果弱酸可以洗脱肿瘤细胞膜表面大部分与MHC-Ⅰ类分子结合的抗原肽;外周血单个核细胞可培养出DC;效靶比40:1时负载膀胱癌抗原肽的DC诱导特异性CTLs可杀伤高达(78.5±7.0)%的BI U-87细胞。结论弱酸可以有效洗脱肿瘤细胞表面的Ⅰ类抗原肽,负载该类多肽的DC在体外可诱导出高效而特异的抗膀胱癌效应。     

幽门螺杆菌感染对胃癌患者外周血MODCs功能的影响

  目的   分析Hp阳性和Hp阴性的胃癌患者外周血单核细胞来源树突状细胞（MODCs）功能的差异性及其临床意义。   方法   用尿素14C呼气试验对解放军第一七四医院2011年1月至2012年10月收治的84例胃癌患者进行Hp感染状态鉴定,分别采集Hp阳性和阴性胃癌患者外周血,分离外周血单个核细胞,采用经典方法（rhGM-CSF、rhIL-4联合rhTNF-α）诱导产生DCs,采用流式细胞仪检测DCs表型,采用LDH释放法检测DCs致敏T细胞对胃癌细胞的毒性杀伤作用,采用ELISA方法检测细胞因子IL-12、IFN-γ的分泌水平。   结果   两组MoDCs成熟过程形态变化无差异,Hp阳性组MoDCs表面标记分子CD1a、CD80、CD83、CD86和HLA-DR平均表达百分率均高于Hp阴性组,其中CD80、CD83、CD86的表达水平差异有统计学意义,CD1a、HLA-DR差异无统计学意义。Hp阳性组DCs致敏T淋巴细胞对胃癌细胞杀伤率和IL-12、IFN-γ的分泌水平均高于Hp阴性组（P < 0.05）。   结论   Hp感染状态不影响胃癌患者外周血MoDCs成熟过程形态变化,Hp感染的胃癌患者MoDCs成熟和活化水平更高      

体外构建的HTA-HSP70BCG冲激的树突状细胞疫苗的抗肿瘤作用

 目的 观察体外构建的榄香烯复合瘤苗抗原-卡介苗热休克蛋白70复合物（H_TA—HSP70_BCG）诱导的树突状细胞疫苗的抗肿瘤效应。方法 来源于小鼠的肝癌Hca-F榄香烯复合疫苗的抗原（HTA）与卡介苗来源的HSPT0（HSP70_BCG）在体外构建成HTA—HSP70_BCG复合物，用GM-CSF和IL-4诱导树突状细胞（DCs），分别用HTA—HSP70_BCG、HTA和HSP70麟对其冲激。用舯法检测该DCs刺激的全脾细胞的增殖活性及被刺激的脾细胞的细胞毒活性。用流式细胞仪检测DCs表面（瑚6和CD40的表达。结果 体外构建HTA—HSP70_BCG可以诱导DCs成熟，表现为DCs表达CD86和CD40上调，该DCs可以刺激全脾细胞增殖并使其产生特异性杀瘤活性，其强度明显大于HTA。结论 体外构建HTA—HSP70麟复合物可以诱导DCs成熟，该DCs可以激活脾细胞产生较强的特异性抗瘤效应。     

自体来源树突状细胞和细胞因子诱导的杀伤细胞混合培养对原代乳腺癌细胞的杀伤作用

 目的　探讨原代乳腺癌细胞冻融抗原负荷自体来源树突状细胞（DC）与细胞因子诱导的杀伤细胞（CIK）细胞混合培养后对原代乳腺癌细胞杀伤活性的影响作用。方法　取对数生长期的原代乳腺癌细胞制备肿瘤抗原（Ag）,用自体外周血单个核细胞分别制备DC 和CIK细胞;用负荷Ag的DC 和CIK细胞共培养,诱导Ag-DC-CIK细胞。采用流式细胞术检测DC免疫表型,MTT法检测分离的单个核细胞（CBMC）、CIK、Ag-CIK和Ag-DC-CIK对原代乳腺癌细胞的杀伤活性。结果　外周血CBMC、CIK、Ag-CIK和Ag-DC-CIK对乳腺癌原代肿瘤细胞杀伤活性分别是（34.35±3.28）%、（45.91±2.78）%、（50.88±3.22）%、（62.10±5.94）%,实验组细胞（Ag-DC-CIK）对原代乳腺癌细胞的杀伤能力（62.10±5.94）%明显高于对照组（P＜0.01）。结论　肿瘤抗原负荷的DC 能增强CIK细胞对靶细胞的杀伤活性,为DC 的免疫治疗提供了新的思路。     

树突状细胞负载的exosome疫苗抗胶质瘤的实验研究

目的：旨在分离胶质瘤细胞释放的exosomes,致敏外周血树突状细胞（dendritic cell,DCs）,观察其对细胞毒性T淋巴细胞（cytotoxic T lymphocytes,CTLs）的激活效应。方法：离心超滤和蔗糖密度梯度离心法分离胶质瘤细胞释放的exosomes,固相免疫电镜法（SPIEM）制备exosomes的MAGE-1及ICAM-1免疫电镜标本。常规方法从外周血单个核细胞诱导DCs并分离T细胞,将胶质瘤细胞来源的exosomes冲击或未冲击的DCs与T细胞共培养。MTT比色法检测体外细胞毒活性。结果：胶质瘤细胞分泌的exosomes为直径50-100nm的膜性微囊,经抗MAGE-1、ICAM-1抗体-胶体金免疫电镜标记,囊外膜可见点状？颗粒状电子致密物沉积。培养后DCs的表面标志物CD1a、HLA-DR、CD83、CD86的表达率较培养前明显升高,差异有显著性（P〈0.05）。exosomes致敏的外周血DCs激活CTLs的能力显著高于肿瘤冻融抗原致敏的DCs组,在效靶比为50：1时,两组CTLs对胶质瘤细胞的杀伤率为70.4%±4.1%vs30.1%±2.8%,（P〈0.05）。结论：胶质瘤细胞分泌的exosomes负载外周血DCs后活化CTLs,发挥抗肿瘤活性,可以作为一种有效的抗胶质瘤免疫治疗策略和方法。     

体外树突状细胞诱导细胞毒T淋巴细胞杀伤肺癌细胞A549的研究

 目的　研究负载有肺癌细胞株A549可溶性抗原并携带外源粒细胞巨噬细胞集落刺激因子（GM-CSF）基因的树突状细胞（DC）在体外激活自身T淋巴细胞形成的细胞毒T淋巴细胞（CTL）对A549细胞的杀伤作用。方法　用肺癌细胞株A549可溶性抗原致敏DC,再用含有GM-CSF外源基因的腺病毒感染DC,将所得的DC与T细胞混合培养以形成对A549细胞有特异杀伤作用的CTL。细胞分为未处理（N-DC）组、加抗原未感染病毒（A-DC）组和加抗原感染病毒（G-A-DC）组。通过测定乳酸脱氢酶（LDH）计算CTL对A549细胞的杀伤率。结果　当CTL与A549细胞,即效应细胞与靶细胞比值（E／T）为5∶1时,N-DC组的杀伤率为（1.9±0.7）%,A-DC组为（21.3±2.6）%,G-A-DC组为（34.5±4.9）%;当E／T为10∶1时,N-DC组的杀伤率为（4.8±0.8）%,U-DC组为（35.4±3.6）%,G-A-DC组为（51.3±2.9）%;E／T为20∶1时,N-DC组的杀伤率为（5.3±0.2）%,A-DC组为（40.5±7.7）%,G-A-DC组为（72.5±4.7）%。3组之间的杀伤率差异有统计学意义（n＝2,F＝356,P＜0.05）,通过两两比较,得出G-A-DC组的杀伤率高于其他两组（P＜0.001）,且A-DC组高于对照组（P＜0.001）。结论　以肺癌细胞株A549可溶性抗原致敏的DC可诱导出对A549具有特异杀伤作用的CTL,当所致敏的DC通过腺病毒感染而带有外源基因GM-CSF时,所诱导的细胞毒杀伤反应进一步增强。     

Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates

We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the immature DCs were pulsed with the purified myeloma cell lysates, and then maturation of the DCs was induced by the addition of a cytokine cocktail. There were no differences in the phenotypic expressions of mature DCs that were generated by pulsing with CD138(+) cell lysates or total cell lysates. In optimization of the concentration of myeloma lysates, DCs pulsed with 10 microg/mL of myeloma lysate had greater allogeneic T-cell stimulatory capacities than those pulsed with higher concentrations of myeloma lysates. The CTL lines generated by DCs pulsed with myeloma lysates demonstrated potent cytotoxic activities against autologous target cells, but not against HLA-A2(-) cell lines or K562 cell lines. The DCs pulsed with myeloma lysates demonstrated a higher stimulatory capacity for autologous CTL compared with mature nonpulsed DCs. These results suggested that the DCs pulsed with purified and optimized myeloma cell lysates could generate potent myeloma-specific CTLs for approaches in MM.     

K-ras 抗原致敏的DC诱导CTL 对胰腺癌体内杀伤活性的研究*

目的:研究K-ras多肽的致敏树突状细胞（DC）活化的特异性细胞毒性T 淋巴细胞（CTL）对胰腺癌的体内外杀伤作用。方法:联合应用粒细胞- 巨噬细胞集落刺激因子和白细胞介素-4 诱导培养外周血DC。表达K-ras突变体的胰腺癌细胞株全瘤、单纯K-ras突变体多肽和K-ras突变体表位肽阳离子纳米颗粒分别致敏DC。致敏DC刺激T 淋巴细胞得到肿瘤抗原特异的细胞毒性T 淋巴细胞（CTL）。 Patu 8988、SW1990细胞系制备荷瘤裸鼠模型评价CTL 体内抗肿瘤活性。结果:负载全瘤抗原的DC其诱导产生的CTL 对胰腺癌有较好的抑制,负载单纯K-ras（12-Val ）突变体多肽、K-ras（12-Val ）突变体表位肽阳离子纳米颗粒的DC其诱导产生的CTL 对表达K-ras（12-Val ）突变体阳性（Patu 8988）的胰腺癌有较特异的抑制作用,而对K-ras（12-Val ）突变体阴性（SW1990）的胰腺癌的抑制作用与对照组比较无显著性差异。结论:负载肿瘤抗原的DC诱导的CTL 可显著提高对荷瘤裸鼠的生存时间,抑制肿瘤的生长速度,并显示其可增加抗肿瘤特异性。      

Antitumor Activity of Lentivirus-mediated Interleukin -12 Gene Modified Dendritic Cells in Human Lung Cancer in Vitro

Objectives: Dendritic cell (DC)-based tumor immunotherapy needs an immunogenic tumor associatedantigen (TAA) and an effective approach for its presentation to lymphocytes. In this study we explored whethertransduction of DCs with lentiviruses (LVs) expressing the human interleukin-12 gene could stimulate antigenspecificcytotoxic T cells (CTLs) against human lung cancer cells in vitro. Methods: Peripheral blood monocytederivedDCs were transduced with a lentiviral vector encoding human IL-12 gene (LV-12). The anticipated targetof the human IL-12 gene was detected by RT-PCR. The concentration of IL-12 in the culture supernatant of DCswas measured by ELISA.Transduction efficiencies and CD83 phenotypes of DCs were assessed by flow cytometry.DCs were pulsed with tumor antigen of lung cancer cells (DC+Ag) and transduced with LV-12 (DC-LV-12+Ag).Stimulation of T lymphocyte proliferation by DCs and activation of cytotoxic T-lymphocytes (CTL) stimulatedby LV-12 transduced DCs pulsed with tumor antigen against A549 lung cancer cells were assessed with methylthiazolyltetrazolium (MTT). Results: A recombinant lentivirus expressing the IL-12 gene was successfullyconstructed. DC transduced with LV-12 produced higher levels of IL-12 and expressed higher levels of CD83than non-transduced. The DC modified by interleukin -12 gene and pulsed with tumor antigen demonstratedgood stimulation of lymphocyte proliferation, induction of antigen-specific cytotoxic T lymphocytes and antitumoreffects. Conclusions: Dendritic cells transduced with a lentivirus-mediated interleukin-12 gene have anenhanced ability to kill lung cancer cells through promoting T lymphocyte proliferation and cytotoxicity.     

Therapeutic effect of MIP-1α-recruited dendritic cells on preestablished solid and metastatic tumors

We previously found that dendritic cell (DC) precursors could be recruited into the peripheral blood of B6 mice by administration of macrophage inflammatory protein (MIP)-1α. These MIP-1α-recruited DCs could induce anti-tumor protective immunity when pulsed with tumor cell lysate. In this study, MIP-1α-recruited DCs could not effectively suppress preestablished tumor when pulsed with B16 tumor cell lysate. However, inoculation with these DCs expressing MAGE-1 induced an anti-tumor immunity against preestablished solid and metastatic tumor from B16-MAGE-1 cells. These MIP-1α-recruited DCs expressed higher level of CCR7 and displayed a more significant chemotactic response toward secondary lymphoid tissue. Therefore, they are superior in the induction of cytotoxic T lymphocytes and the inhibition of tumor development and metastasis than bone marrow-derived DCs. This study established a novel approach to the treatment of preestablished solid and metastatic tumors using MIP-1α-recruited DCs transduced with tumor antigen gene.     

抑制SOCS1联合OK-432刺激的DC疫苗抗肿瘤效应的初步研究

BACKGROUND & OBJECTIVE: Suppressor of cytokine signaling 1 (SOCS1) plays a critical role in antitumor immunity. Down-regulating SOCS1 in antigen-presenting dendritic cells (DCs) could enhance antigen-specific antitumor immunity. This study was to investigate the antigen-specific antitumor effect and mechanism of DCs with siRNA-mediated inhibition of SOCS1, stimulated by OK-432 and pulsed with hepatocellular carcinoma cell line HepG2 antigens. METHODS: The expression of SOCS1 in immature DCs was down-regulated by RNA interference (RNAi). DCs were pulsed with lysate of HepG2 cells and stimulated with OK-432. The morphology of DCs was observed under converted phase microscopy. Phenotypic changes in cells after stimulation were characterized by flow cytometry (FCM). The Alamar Blue assay was adopted to evaluate the activation and proliferation of autologous lymphocytes induced by mature DCs. The cytotoxicity of cytotoxic T lymphocytes (CTLs) elicited by modified DCs to HepG2, EC109 and K562 cells was tested by the lactate dehydrogenase (LDH) assay. RESULTS: Cells displaying a typical morphology and phenotypic properties of mature DCs were obtained successfully. The expression of SOCS1 in DCs was down-regulated by SOCS1 RNAi. Mature DCs showed high expressions of CD80, CD83, CD86, and HLA-DR. Pulsing of DCs with lysate of HepG2 had no influence on the phenotypic properties of DCs. Down-regulating SOCS1 expression enhanced the maturation of DCs. The modified DC tumor vaccine stimulated the proliferation of autologous lymphocytes effectively, and the proliferation rate of T cells was (110.7+/-22.2)%. After being activated by modified DCs, TCLs exerted a specific and effective killing effect on HepG2 cells, but not on EC109 and K562 cells. CONCLUSION: Mature DCs could induce antigen-specific antitumor immunity against hepatocellular carcinoma after silencing of SOCS1 by siRNA, stimulation by OK-432 and pulsing of DCs with HepG2 cell antigens.     

Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells

Dendritic cells play a major role in cellular immunity. The crucial steps of antigen presentation and processing by DCs may be limiting factors for adoptive cellular immunotherapy. Here, we investigated whether hyperthermia of human hepatocellular carcinoma (HCC) cells induces enhanced cytotoxic cellular immune response. Peripheral blood mononuclear cell (PBMC)-derived DCs were pulsed with tumor cell lysate of the human HCC cell line HepG2, which had been heat shocked prior to incubation for 5 h. Subsequent to TNFalpha-induced maturation DCs were co-cultured with autologous CD4+ and/or CD8+ cells, and T cell mediated cytolysis of HepG2 cells was assessed. We observed enhanced CD4+/8+ cellular cytotoxicity against HepG2 cells subsequent to co-culture with the heat shocked tumor lysate pulsed DCs as compared to pulsing DCs with lysate of non-heat shocked tumor cells. The improved cellular immune response can be related to enhanced expression of HSP 70 and 90 in HepG2 cells upon hyperthermia.     

Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells

Dendritic cell (DC)/tumor cell fusion vaccine has been revealed as a promising tool for the antitumor immunotherapy. Previous research has shown that fusion hybrids of human DCs and autologous tumor cells can induce cytotoxic T lymphocyte (CTL) responses against autologous tumor cells in animal models and human clinical trials. However, a major restriction factor for the clinical use is the difficulty for preparation of sufficient amount of autologous tumor cells especially for the patients with metastasis cancer whose primary tumor lesion is not clear or has been resected. In this study, allogeneic breast cancer cell line MCF-7 cells were electrofused to autologous DCs from patient with breast cancer as a strategy to deliver shared breast cancer antigens to DCs. Fusion cells generated by autologous DCs and allogeneic MCF-7 were able to induce autologous T lymphocytes proliferation, high levels of IFN-gamma production and CTL responses. CTLs induced by DCs/allogeneic MCF-7 fusion cells were able to kill autologous breast cancer cells in an antigen specific and HLA restriction manner. Our study may provide the experiment basis for the use of allogeneic breast cancer cell line in the DC/tumor cell fusion cell vaccination strategy.